ArticleEuropean radiology2019
Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma.
Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Prediction of H3 K27M-mutant in midline gliomas by magnetic resonance imaging: a systematic review and meta-analysis.Neuroradiology · 2022Pooled it
- Amide proton transfer-weighted magnetic resonance imaging for the diagnosis of triple-negative breast cancer: a comparative study with diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2026Article
- Radiomic correlates with overall survival in glioblastoma: amide proton transfer (APT) imaging-based feature analysis and integration of clinical factors.Physical and engineering sciences in medicine · 2026Article
- FlexCENT: A frequency-flexible CEST imaging network combining frequency offset encoding and three-dimensional U-Net.Magnetic resonance letters · 2026Article
- Assessment of multimodal CEST, perfusion and diffusion MRI for predicting clinical outcome of patients with diffuse glioma following surgery at baseline before radiotherapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Grading of glioma and prediction of IDH mutation status via longitudinal relaxation time in rotating frame mapping on 5-T magnetic resonance imaging: added value to amide proton transfer-weighted imaging.Quantitative imaging in medicine and surgery · 2026Article
- Review
- MixBranchNet: a task-adaptive network for glioma segmentation and genotype prediction by exploiting spatial-spectral correlations in CEST MRI.Frontiers in oncology · 2026Article
- Prediction of MGMT promoter methylation in glioblastoma and grade 4 astrocytoma using fluid-suppressed chemical exchange saturation transfer MRI and machine learning-based segmentation.Frontiers in oncology · 2026Article
- Metabolic, perfusion, and diffusion imaging enhance diagnosis and prognosis of H3K27-altered diffuse midline gliomas.BMC medicine · 2025Article
- 3-Tesla amide proton transfer-weighted imaging (APT-WI): elevated signal also in tumor mimics.European radiology · 2025Article
- Role of Amide Proton Transfer Weighted MRI in Predicting MGMTp Methylation Status, p53-Status, Ki-67 Index, IDH-Status, and ATRX Expression in WHO Grade 4 High Grade Glioma.Tomography (Ann Arbor, Mich.) · 2025Article
- Article
- A window into the brain: multimodal MRI assessment of vascular cognitive impairment.Frontiers in neuroscience · 2025Review
- Advanced imaging techniques and non-invasive biomarkers in pediatric brain tumors: state of the art.Neuroradiology · 2024Review
- Article
- Utilizing the amide proton transfer technique to characterize diffuse gliomas based on the WHO 2021 classification of CNS tumors.The neuroradiology journal · 2024Article
- Amide proton transfer-weighted imaging and derived radiomics in the classification of adult-type diffuse gliomas.European radiology · 2024Article
- Whole-tumor histogram analysis of synthetic magnetic resonance imaging predicts isocitrate dehydrogenase mutation status in gliomas.Quantitative imaging in medicine and surgery · 2024Article
- Radiomic feature reliability of amide proton transfer-weighted MR images acquired with compressed sensing at 3T.International journal of imaging systems and technology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
objectivesTo assess the utility of amide proton transfer (APT) imaging as an imaging biomarker to predict prognosis and molecular marker status in high-grade glioma (HGG, WHO grade III/IV).
methodsWe included 71 patients with pathologically diagnosed HGG who underwent preoperative MRI with APT imaging. Overall survival (OS) and progression-free survival (PFS) according to APT signal, clinical factors, MGMT methylation status, and IDH mutation status were analyzed. Multivariate Cox regression models with and without APT signal data were constructed. Model performance was compared using the integrated AUC (iAUC). Associations between APT signals and molecular markers were assessed using the Mann-Whitney test.
resultsHigh APT signal was a significant predictor for poor OS (HR = 3.21, 95% CI = 1.62-6.34) and PFS (HR = 2.22, 95% CI = 1.33-3.72) on univariate analysis. On multivariate analysis, high APT signals were an independent predictor of poor OS and PFS when clinical factors alone (OS: HR = 2.89; PFS: HR = 2.13), or in combination with molecular markers (OS: HR = 2.85; PFS: HR = 2.00), were included as covariates. The incremental prognostic value of APT signals was significant for OS and PFS. IDH-wild type was significantly associated with high APT signals (p = 0.001) when compared to IDH-mutant; however, there was no difference based on MGMT methylation status (p = 0.208).
conclusionHigh APT signal was a significant predictor of poor prognosis in HGG. APT data showed significant incremental prognostic value over clinical prognostic factors and molecular markers and may also predict IDH mutation status. KEY POINTS: • Amide proton transfer (APT) imaging is a promising prognostic marker of high-grade glioma. • APT signals were significantly higher in IDH-wild type compared to IDH-mutant high-grade glioma. • APT imaging may be valuable for preoperative screening and treatment guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.